Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Deferasirox in Combination With Desferoxamine in β-thalassaemia Patients With Severe Cardiac Iron Overload

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients with β-thalassemia major, at least 18 years old, having given written consent to participate in the study.~* Cardiac MRI T2\* value ranging from \<=4 to \<=10 ms.~* LVEF ≥ 56 % as determined by CMR.~* Patients with LIC \> 10mg Fe/g dw will be included in the protocol. Study will evaluate the first 10 patients at 6 months, and if no safety signals are present, patients with LIC\>5 mg Fe/g dw will be allowed to be included.~* Prior iron chelation treatment with DFO, DFP, DFX or combination DFO-DFP~Exclusion Criteria:~* Patients with symptoms of cardiac dysfunction symptoms (shortness of breath at rest or exertion, orthopnea, exercise intolerance, lower extremity edema, arrhythmias).~* Patients with cardiac T2\* MRI \< 4 or \> 10 ms.~* Patients not compliant to intensive iron chelation therapy regimens such i.v DFO 24 hr infusions or DFO-DFP combination.~* Patients with documented liver failure (presence of portal hypertension, hepatic edemas, ascites).~* Patients unable to undergo study assessments, including blood sampling, MRI, e.g., are claustrophobic to MRI, have a pacemaker, ferromagnetic metal implants other than those approved as safe for use in MRI scanners (e.g., some types of aneurysm clips, shrapnel in proximity to vital organs such as the retina), are obese (exceeding the equipment limits).~* Patients with serum creatinine \> ULN or with significant proteinuria as indicated by a urinary protein/creatinine ratio ≥ 1.0 in a non-first void urine sample at baseline. Patients with creatinine clearance \<60 ml/min will be excluded.~* Patients with ALT (SGPT) levels \> 5 x ULN.~* Patients with considerable impaired gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral deferasirox / ICL670 (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection.~* History or clinical evidence of pancreatic injury or pancreatitis.~* Patients with a known hypersensitivity to any of the study drugs or the drug's excipients.~* History of clinically relevant ocular and/or auditor toxicity related to iron chelation therapy.~* Patients with psychiatric or addictive disorders which prevent them from giving their informed consent or undergoing any of the treatment options or patients unwilling or unable to comply with the protocol.~* Patients with a known history of HIV seropositivity (Elisa or Western blot).~* History of malignancy of any organ system, treated or untreated, within the past 5 years whether or not there is evidence of local recurrence or metastases, with the exception of localized basal cell carcinoma of the skin.~* Female patients who are pregnant or breast feeding.~* Female patients of reproductive potential not employing an effective method of birth control. Women of childbearing potential must have a negative serum pregnancy test ≤ 48 hours prior to the study drugs.~* Patients participating in another clinical trial or receiving an investigational drug.~* History of non-compliance with medical regimens or patients who are considered potentially unreliable and/or not cooperative, unwilling or unable to comply with the protocol.~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Deferasirox / Deferasirox + Deferoxamine (DFO) (Type: EXPERIMENTAL): During Phase A, the induction treatment at entry, participants received Deferasirox -DFO combination. During Phase B, when participants transitioned to less intensive chelation therapy, participants received Deferasirox monotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).